Shilpa Gupta, MD, presented “Implications of EV 302 How do We Sequence Treatment in the Future” at the 7th International Bladder Cancer Update on December 6, 2024, in Dallas, Texas.
How to cite: Gupta, Shilpa. “Implications of EV 302 How do We Sequence Treatment in the Future” December 2024. Accessed Mar 2025. https://grandroundsinurology.com/implications-of-ev-302-how-do-we-sequence-treatment-in-the-future/
Implications of EV 302 How do We Sequence Treatment in the Future – Summary
Shilpa Gupta, MD, explores the evolving treatment paradigm in metastatic urothelial carcinoma following the EV-302 trial.
In this 6-minute presentation, Dr. Gupta reviews past treatment paradigms, explaining that, before the EV-302 trial, cisplatin-eligible patients typically received cisplatin-based chemotherapy followed by immunotherapy upon progression.
The current treatment paradigm prioritizes EV plus pembrolizumab as the frontline standard, followed by platinum-based chemotherapy upon progression. Dr. Gupta stresses that future research must optimize treatment sequences and develop novel therapies for patients who progress on EV plus pembrolizumab. Comprehensive genomic and IHC testing is essential for guiding treatment decisions and ensuring patients receive targeted therapies.
About the 7th International Bladder Cancer Update:
The International Bladder Cancer Update (IBCU) is a CME conference focused on the diagnosis and treatment of bladder cancer. The conference offers medical professionals an opportunity to listen to updates from, and interact with, expert international faculty to improve knowledge and determine best treatment practices to improve patient outcomes. IBCU encompasses expert lectures, interactive discussions, a panel roundtable, debates, and case presentations. It is physician-led, multi-supported, and designed for urologists, urologic oncologists, and other healthcare professionals involved in the treatment of bladder cancer.
For further educational activities from this conference, visit our collection page.
ABOUT THE AUTHOR
Shilpa Gupta, MD, obtained her Medical Degree at the Lady Hardinge Medical College in New Delhi, India and completed a residency in Internal Medicine at the University of Connecticut Health Center. She completed Hematology-Oncology fellowship at Georgetown University and Thomas Jefferson University followed by a Genitourinary Oncology Translational Research fellowship at Thomas Jefferson University. Dr. Shilpa Gupta is currently the Director of the Genitourinary Medical Oncology at Taussig Cancer Institute and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic.
Dr. Gupta’s research interests are novel drug development and understanding biomarkers of response and resistance to therapies in bladder cancer. Dr. Gupta has led several Investigator Initiated Trials in Genitourinary Cancers and has leadership roles in NCI trials and is Chair of an Alliance led phase 3 trial in Bladder Cancer, Co-Chair of SWOG S1206 trial in Prostate Cancer and SWOG champion of the Alliance A031701 trial in Bladder Cancer. She is Principal Investigator of 2020 Department of Defense Idea Award to study the biomarkers of response and resistance to immunotherapy in bladder cancer and Co-Principal Investigator of Department of Defense Team Translational Science Award to study immunotherapy combination strategies to overcome resistance in bladder cancer. Dr. Gupta is the Co-Chair of the Hoosier Cancer Research Network (HCRN) Genitourinary Working Group and Co-Chair of the Case Comprehensive Cancer Center PRMC committee.
Dr. Gupta’s research has been published in peer-reviewed journals including the Journal of Clinical Oncology, Lancet Oncology, Clinical Cancer Research, European Oncology, among others. She is the author for the AUA core curriculum for penile cancer and serves on the NCCN Guidelines Panel for Prostate Cancer. Dr. Gupta is active in several professional organizations including the American Society of Clinical Oncology (ASCO), American Urologic Association (AUA), American Association of Cancer Research (AACR), Society of Urologic Oncology (SUO), Society of Immunotherapy for cancer (SITC), Bladder Cancer Advocacy Network (BCAN), Prostate Cancer Foundation (PCF) and the European society of Medical Oncology (ESMO).
